Focal segmental glomerulosclerosis epidemiology and demographics

Focal segmental glomerulosclerosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Focal segmental glomerulosclerosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X-Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Focal segmental glomerulosclerosis epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Focal segmental glomerulosclerosis epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Focal segmental glomerulosclerosis epidemiology and demographics
CDC on Focal segmental glomerulosclerosis epidemiology and demographics
Focal segmental glomerulosclerosis epidemiology and demographics in the news
Blogs on Focal segmental glomerulosclerosis epidemiology and demographics
Directions to Hospitals Treating Focal segmental glomerulosclerosis
Risk calculators and risk factors for Focal segmental glomerulosclerosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Incidence

• The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
• In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

• The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
• In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
• The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

• In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
• The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

FSGS is considered a disease of the adult population (compared to minimal change disease which is more common among children). The median age of non-HIV associated FSGS leading to ESRD is 40-49 years in black adults and 70-79 in white and Asian adults.

Gender

• Men are more commonly affected by focal segmental glomerulosclerosis than women
• The prevalence of FSGS male to female ratio is 1.5-2 to 1

Race

FSGS is the most common primary renal cause of end-stage renal disease (ESRD) in whites and blacks, contributing to approximately 2% of ESRD. FSGS is more common in blacks. It accounts for approximately 35% of nephrotic syndromes in all cases and approximately 50% of nephrotic syndrome in blacks. FSGS seems to have a higher incidence in Blacks with a familial pattern of inheritance especially in Blacks with family history of ESKD.